We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA is proposing in a draft guidance to bar any person with more than $50,000 in ties to medical device and drug companies from participating in an agency advisory committee.
Analysts at RBC Capital Markets say Abbott Laboratories has "the best stent," after data released last week at the American College of Cardiology indicate that Abbott's Xience is superior to Boston Scientific's Taxus.
One of the biggest mistakes a medical device company can make when using an independent sales force is neglecting the situation where sales representatives are disinclined to do the legwork of building up a product's market when the manufacturer is likely to sell out to a bigger company or switch to a direct sales force, according to Rick Davies, managing partner at Vector Resources.
Sen. Chris Dodd (D-Conn.) reintroduced a bill to improve incentives for developing pediatric medical devices so children are not left with "one-size-fits-all" products.
SynCardia Systems announced it recruited five leading biomedical scientists and physicians to review its temporary total artificial heart -- the world's first -- and help keep the device "state-of-the-art," the company said.
The FDA is proposing in a draft guidance to bar any person with more than $50,000 in ties to device and drug companies from participating in an agency advisory committee.